The Science Behind Drugs to Treat CLL: How Biological Understanding Transformed Therapy

Key Takeaways

• Chronic lymphocytic leukemia (CLL) is a slow-growing blood cancer of B lymphocytes driven by impaired programmed cell death (apoptosis), abnormal survival signaling, and interactions with the surrounding immune microenvironment.
• Traditional chemotherapy attacks rapidly dividing cells non-selectively, whereas modern targeted therapies block specific molecular pathways that CLL cells depend on for survival.
• Two major therapeutic targets are Bruton tyrosine kinase (BTK), a key component of B-cell receptor (BCR) signaling, and the anti-apoptotic protein BCL-2.
• BTK inhibitors—including zanubrutinib (BRUKINSA®), acalabrutinib (Calquence®), ibrutinib (Imbruvica®), and pirtobrutinib (Jaypirca®)—have transformed CLL treatment by interrupting survival signaling.
• Venetoclax (Venclexta®), a BCL-2 inhibitor, restores the ability of leukemia cells to undergo programmed cell death and is commonly used in fixed-duration combination regimens.
• Genetic testing for TP53 mutations, deletion 17p [del(17p)], and immunoglobulin heavy chain variable region (IGHV) mutation status helps guide treatment decisions and predict response to therapy.
• Measurable residual disease (MRD) testing can detect very low levels of remaining leukemia cells and provides valuable information about the depth of response after treatment.
• Ongoing research is focused on optimizing combination therapies, overcoming drug resistance, shortening treatment duration when appropriate, and developing new immune-based therapies.

Introduction

Chronic lymphocytic leukemia (CLL) is the most common leukemia diagnosed in adults in many Western countries. It develops when mature B lymphocytes acquire genetic and molecular abnormalities that allow them to survive much longer than normal. Instead of undergoing their natural life cycle, these abnormal cells gradually accumulate in the blood, bone marrow, lymph nodes, and spleen.

Infographic illustrating the molecular pathways that drive chronic lymphocytic leukemia (CLL) and how targeted therapies—including BTK inhibitors and the BCL-2 inhibitor venetoclax—interrupt leukemia cell survival and restore programmed cell death.

Unlike many cancers, CLL often progresses slowly. Many people have no symptoms when they are diagnosed, and the disease may be discovered incidentally during routine blood work. In these individuals, immediate treatment is often unnecessary. Instead, physicians frequently recommend active surveillance, sometimes called watchful waiting, which involves regular physical examinations, blood tests, and monitoring for symptoms. Numerous studies have shown that beginning treatment before it becomes medically necessary does not improve survival for most patients with early-stage, asymptomatic CLL (Hallek et al., 2018).

Treatment is generally recommended only when the disease begins causing symptoms, progressive enlargement of lymph nodes or the spleen, worsening blood counts, recurrent infections, or other signs that it is becoming more active.

Over the past two decades, scientific advances have fundamentally reshaped the management of CLL. Instead of relying primarily on chemotherapy, researchers have identified the specific molecular pathways that leukemia cells depend on for survival. These discoveries have led to targeted therapies that interfere with the biology of the disease while often causing fewer toxic effects than conventional chemotherapy. Today, treatment decisions increasingly incorporate each patient’s genetic profile, overall health, and disease characteristics, reflecting the growing role of precision medicine in hematologic oncology.

This article explains the biological mechanisms that drive CLL, how modern therapies interrupt those pathways, why genetic testing has become an essential part of treatment planning, and how ongoing research continues to improve outcomes for patients.

What Happens at the Cellular Level?

Healthy B lymphocytes are an essential part of the immune system. After helping the body fight infection, these cells normally undergo programmed cell death (apoptosis), preventing unnecessary accumulation.

In CLL, this tightly regulated process breaks down. Rather than dying when they should, leukemia cells receive continuous signals that promote survival while resisting apoptosis. Over time, these long-lived cells accumulate throughout the body.

Researchers have identified several interconnected biological mechanisms responsible for this abnormal behavior. Over the past decade, studies of CLL biology have shown that abnormal B-cell receptor signaling, resistance to apoptosis, genetic alterations, and continuous support from the surrounding tumor microenvironment all work together to promote the survival and accumulation of leukemia cells. These discoveries laid the biological foundation for the development of modern targeted therapies that interrupt these pathways rather than relying solely on conventional chemotherapy (Zhang & Kipps, 2014).

B-Cell Receptor Signaling

One of the central pathways involved is B-cell receptor (BCR) signaling.

Under normal circumstances, B-cell receptors recognize foreign antigens and activate immune responses only when needed. In CLL, however, this signaling pathway often remains chronically active, even in the absence of infection. Continuous activation stimulates cell survival, growth, migration, and interactions with supportive tissues inside lymph nodes and bone marrow.

Several proteins participate in this signaling cascade, including Bruton tyrosine kinase (BTK), phosphoinositide 3-kinase (PI3K), and spleen tyrosine kinase (SYK). Because BTK occupies a pivotal position within the pathway, it became one of the earliest and most successful therapeutic targets.

BCL-2 and Resistance to Cell Death

Another hallmark of CLL is overexpression of the B-cell lymphoma 2 (BCL-2) protein.

BCL-2 functions as a natural regulator of apoptosis. In healthy cells, it helps balance survival and cell death. In CLL, however, excessive BCL-2 production blocks apoptosis, allowing abnormal lymphocytes to survive despite accumulating genetic damage.

This discovery was particularly important because it identified a vulnerability that could be targeted directly with medication.

The Tumor Microenvironment

CLL cells do not survive independently. They receive continuous support from surrounding cells within the bone marrow, lymph nodes, and spleen—a network collectively known as the tumor microenvironment.

Nurse-like cells, stromal cells, T lymphocytes, and cytokines provide survival signals that protect leukemia cells from apoptosis and reduce the effectiveness of treatment. This interaction partly explains why leukemia cells often survive longer inside lymph nodes than they do in laboratory conditions.

Modern therapies increasingly aim not only to kill leukemia cells directly but also to disrupt these supportive interactions. Recognition of the central role played by the tumor microenvironment has fundamentally changed how researchers understand CLL progression and continues to influence the development of new therapeutic strategies (Zhang & Kipps, 2014).

Genetic Abnormalities

Not all CLL behaves the same way.

Differences in genetic and chromosomal abnormalities help explain why some patients live for decades without requiring treatment while others experience more aggressive disease.

Among the most clinically important abnormalities are:

• TP53 mutations
• Deletion of chromosome 17p [del(17p)]
• IGHV mutation status
• Complex karyotype in selected patients

Patients with TP53 abnormalities or del(17p), for example, generally respond poorly to traditional chemotherapy but often benefit from modern targeted therapies. Consequently, current NCCN Clinical Practice Guidelines recommend evaluating these biomarkers before initiating treatment because they play a major role in selecting the most appropriate therapy and avoiding treatments that are less effective in patients with high-risk disease (Wierda et al., 2024).

From Broad Chemotherapy to Precision Therapy

For decades, chemotherapy formed the foundation of CLL treatment.

Chemotherapy drugs damage DNA or interfere with cell division in rapidly growing cells. Although this approach can eliminate leukemia cells, it also affects many healthy tissues, including bone marrow, hair follicles, and the lining of the digestive tract. As a result, patients may experience anemia, infections, hair loss, nausea, and other well-recognized adverse effects.

Advances in molecular biology fundamentally changed this treatment paradigm by revealing the specific molecular pathways that CLL cells depend upon for survival.

Instead of indiscriminately attacking all rapidly dividing cells, targeted therapies focus on proteins that leukemia cells depend on much more heavily than normal cells. By selectively interrupting these critical survival pathways, targeted agents have improved disease control for many patients while often producing a different—and in many cases more manageable—side-effect profile than traditional chemotherapy.

This shift represents one of the clearest examples of precision medicine in cancer care, where treatment is increasingly guided by the biological characteristics of an individual’s disease rather than by diagnosis alone.

As a result, targeted therapies have largely replaced chemoimmunotherapy as the preferred initial treatment for many patients with CLL, particularly those with high-risk genetic features or significant coexisting medical conditions.

Key Biological Targets and Available Drugs

Targeting B-Cell Receptor Signaling: BTK Inhibitors

One of the earliest and most influential applications of this biological understanding was the development of Bruton tyrosine kinase (BTK) inhibitors.

BTK is a key enzyme within the B-cell receptor signaling pathway. Blocking BTK interrupts the continuous survival signals that leukemia cells rely upon, reducing their ability to proliferate and remain protected within lymphoid tissues.

Patients beginning BTK inhibitor therapy may notice that their lymphocyte count temporarily increases during the first weeks of treatment. This phenomenon, known as redistribution lymphocytosis, occurs because leukemia cells leave the lymph nodes and enter the bloodstream after losing supportive survival signals. Although the blood count initially rises, this generally reflects the drug’s mechanism of action rather than disease progression.

Several BTK inhibitors are approved for treating CLL or the closely related condition small lymphocytic lymphoma (SLL), including:

• BRUKINSA® (zanubrutinib)
• Calquence® (acalabrutinib)
• Imbruvica® (ibrutinib)
• Jaypirca® (pirtobrutinib), a non-covalent BTK inhibitor primarily used after prior BTK inhibitor therapy in appropriate patients

Although all of these medications target BTK, they are not interchangeable. They differ in kinase selectivity, dosing schedules, adverse-effect profiles, drug interactions, and the clinical evidence supporting their use in different treatment settings. When selecting therapy, clinicians consider multiple factors, including cardiovascular risk, kidney function, prior treatments, coexisting medical conditions, genetic findings such as TP53 alterations, and individual patient preferences.

For many patients, BTK inhibitors have substantially improved long-term disease control while reducing the need for conventional chemotherapy. As evidence from large clinical trials accumulated, regulatory approvals expanded to include newer BTK inhibitors with improved selectivity. Reflecting the growing evidence supporting newer BTK inhibitors, the U.S. Food and Drug Administration approved zanubrutinib for adults with CLL or SLL in 2023 after clinical trials demonstrated significant efficacy in both previously untreated and relapsed disease (FDA, 2023).

Restoring Apoptosis: BCL-2 Inhibition

The discovery that CLL cells rely heavily on the anti-apoptotic protein BCL-2 led to another major therapeutic breakthrough.

Venetoclax (Venclexta®) binds directly to BCL-2, displacing pro-apoptotic proteins and allowing leukemia cells to undergo their natural process of programmed cell death.

Because venetoclax can eliminate leukemia cells rapidly, treatment begins with a carefully monitored dose-escalation schedule designed to reduce the risk of tumor lysis syndrome, a potentially serious complication caused by the rapid breakdown of cancer cells.

Venetoclax is frequently combined with anti-CD20 monoclonal antibodies such as obinutuzumab or, in some clinical settings, with BTK inhibitors. These combinations can produce deep remissions, including undetectable measurable residual disease (MRD), allowing many patients to complete treatment after a predetermined period rather than remaining on continuous therapy.

Other Targeted and Immune-Based Therapies

Several additional treatment approaches continue to expand the therapeutic landscape.

Anti-CD20 monoclonal antibodies, including obinutuzumab and rituximab, enhance immune-mediated destruction of leukemia cells and are often combined with targeted therapies.

PI3K inhibitors remain treatment options for selected patients, although their use has become more limited because immune-mediated adverse effects—including colitis, pneumonitis, hepatotoxicity, and severe infections—have reduced their role as newer targeted therapies with improved safety profiles have become available.

Researchers are also evaluating CAR T-cell therapy, bispecific antibodies, and other immune-based strategies for patients with relapsed or treatment-resistant disease. While these approaches remain under active investigation, they represent promising efforts to harness the immune system against CLL.

Continuous Versus Fixed-Duration Therapy

One important question patients often ask is whether treatment must continue indefinitely.

The answer depends on the therapy being used.

Most BTK inhibitors are administered continuously because they suppress leukemia cell survival but generally do not eliminate every malignant cell. Treatment therefore continues as long as it remains effective and well tolerated.

In contrast, venetoclax-based combinations are commonly given for a fixed duration, often 12 to 24 months depending on the treatment regimen. These approaches aim to achieve deep remissions, including undetectable MRD, allowing therapy to stop while patients remain under careful observation.

Neither strategy is universally superior. Instead, physicians individualize treatment based on disease biology, treatment goals, potential adverse effects, patient preferences, and the likelihood of long-term disease control.

Precision Medicine in CLL Care

Modern CLL management increasingly relies on precision medicine, in which treatment decisions are guided by the unique biological features of an individual’s leukemia.

Before initiating therapy, current guidelines recommend testing for important biomarkers such as:

• TP53 mutations
• Deletion 17p [del(17p)]
• IGHV mutation status

These biomarkers help estimate prognosis and identify therapies that are more likely to provide durable benefit. For example, patients with TP53 abnormalities generally derive less benefit from traditional chemoimmunotherapy and are more often treated with targeted agents.

Although genetic testing cannot predict exactly how an individual patient will respond, it has become an essential component of treatment planning and helps clinicians tailor therapy to each person’s disease.

Patients are encouraged to discuss these test results with their hematologist before beginning treatment, as they can significantly influence both the initial treatment strategy and future therapeutic options.

Treatment decisions also take into account age, overall health, cardiovascular risk, kidney function, previous therapies, and individual preferences, underscoring that no single treatment approach is appropriate for every patient.

Clinical Research Directions and Monitoring Response

Ongoing Research

Although targeted therapies have transformed CLL management, researchers continue to investigate ways to improve long-term outcomes while reducing treatment burden and minimizing adverse effects.

Current areas of research include:

• Combining BTK inhibitors with BCL-2 inhibitors to achieve deeper remissions.
• Determining which patients benefit most from fixed-duration versus continuous therapy.
• Understanding and overcoming mechanisms of drug resistance.
• Developing next-generation BTK inhibitors with greater selectivity and activity against resistant disease.
• Expanding the role of immune-based therapies, including CAR T-cell therapy and bispecific antibodies.
• Identifying new molecular targets through advances in genomics and tumor biology.

Drug resistance has become one of the major research priorities in CLL. Investigators are studying how acquired mutations in BTK, PLCG2, BCL-2, and other signaling pathways enable leukemia cells to evade targeted therapies after prolonged treatment. Understanding these resistance mechanisms is guiding the development of next-generation BTK inhibitors, novel BCL-2 inhibitors, and rational combination therapies designed to delay or overcome treatment failure (Blombery et al., 2025).

Large clinical trials continue to evaluate whether combination regimens can safely shorten treatment duration while maintaining durable disease control. As additional evidence becomes available, clinical practice guidelines continue to evolve.

Why Measurable Residual Disease (MRD) Matters

Historically, physicians assessed treatment response primarily through physical examination, blood counts, imaging studies when appropriate, and bone marrow evaluation.

Today, measurable residual disease (MRD) testing provides a much more sensitive way to determine how much leukemia remains after treatment.

MRD testing uses highly sensitive laboratory techniques—most commonly multiparameter flow cytometry or next-generation sequencing—to detect very small numbers of leukemia cells that cannot be identified using conventional methods. In many cases, these tests can detect one leukemia cell among 10,000 or even 100,000 normal cells.

When no leukemia cells are detected at the limits of the test, the result is referred to as undetectable MRD (uMRD).

Multiple clinical studies have demonstrated that patients who achieve uMRD after treatment generally experience longer progression-free survival than those with detectable residual disease (Rios-Olais et al., 2024). However, uMRD does not mean that CLL has been cured. Small numbers of leukemia cells may remain below the detection threshold, and some patients eventually experience disease recurrence.

MRD testing is particularly useful in clinical trials evaluating fixed-duration treatment regimens because it provides an objective measure of the depth of response. Although MRD assessment is increasingly incorporated into research and some clinical decision-making, it complements rather than replaces traditional clinical evaluation. Physicians interpret MRD findings alongside symptoms, laboratory values, imaging when indicated, genetic risk factors, and the patient’s overall health.

As testing methods become increasingly standardized, MRD assessment is expected to play an even greater role in future clinical trials and treatment strategies.

Where the Science Is Headed

The understanding of CLL has evolved from viewing it as a single disease to recognizing it as a biologically diverse group of disorders influenced by genetics, intracellular signaling pathways, and interactions with the immune microenvironment.

This deeper understanding continues to shape drug development.

Although targeted therapies have dramatically improved outcomes, important questions remain. Researchers are working to understand why some patients develop drug resistance while others experience durable remissions, and whether carefully selected drug combinations can produce deeper responses with shorter treatment durations. Advances in genomic profiling and computational biology are also helping identify new therapeutic targets and may eventually allow treatment to be tailored even more precisely to each patient’s disease.

Although important challenges remain, the pace of scientific progress in CLL continues to accelerate, offering new opportunities to improve both survival and quality of life.

Related Reading:

The Future of Leukemia Treatment: How Base-Edited T-Cells are Making a Difference

Hiroshima University Finds a New Way to Prevent Relapse of Chronic Myeloid Leukemia (CML)

Gene Editing as a Novel Approach in the Treatment of Acute Leukemias

Final Thoughts

The evolution of CLL treatment demonstrates how advances in basic science can transform patient care. A deeper understanding of the molecular pathways that drive leukemia cell survival has shifted treatment away from broad-spectrum chemotherapy toward targeted therapies that interfere with the specific mechanisms cancer cells depend upon. Today, treatment decisions increasingly incorporate genetic testing, disease biology, and patient-specific factors to provide a more personalized approach to care.

Although CLL remains a chronic disease for most patients, ongoing research continues to improve our understanding of treatment resistance, measurable residual disease, and the optimal sequencing of targeted therapies. Continued collaboration among laboratory scientists, clinical investigators, and healthcare professionals will be essential for translating new biological discoveries into safer, more effective, and increasingly personalized treatments for people living with CLL.

FAQs

Understanding CLL

What is chronic lymphocytic leukemia (CLL)?

Chronic lymphocytic leukemia (CLL) is a type of blood cancer that affects B lymphocytes, a kind of white blood cell responsible for producing antibodies. In CLL, these cells accumulate because they survive much longer than normal rather than because they divide rapidly. The disease usually progresses slowly and primarily affects older adults.

Why is CLL considered a slow-growing cancer?

Unlike many cancers, CLL often develops over many years. Many people have no symptoms when they are diagnosed, and the disease is frequently discovered during routine blood tests. Some patients may never require treatment, while others eventually develop symptoms or disease progression that necessitates therapy.

Why don’t all patients need treatment immediately after diagnosis?

Early treatment has not been shown to improve survival for most people with asymptomatic, early-stage CLL. Instead, doctors often recommend active surveillance, also known as watchful waiting, with regular blood tests and physical examinations until treatment becomes medically necessary.

The Biology of CLL

Why do leukemia cells survive instead of dying normally?

Healthy B lymphocytes undergo programmed cell death, known as apoptosis, after completing their immune function. In CLL, genetic and molecular abnormalities allow these cells to resist apoptosis while continuously receiving signals that promote their survival, leading to their gradual accumulation.

What is B-cell receptor (BCR) signaling, and why is it important?

The B-cell receptor helps normal immune cells recognize foreign substances and respond to infections. In CLL, this signaling pathway often remains abnormally active, providing continuous survival signals that allow leukemia cells to grow, migrate, and resist cell death.

What role does the BCL-2 protein play in CLL?

BCL-2 is a protein that helps regulate cell survival. In CLL, excessive amounts of BCL-2 prevent leukemia cells from undergoing apoptosis, allowing them to survive much longer than they should. This discovery led to the development of drugs that specifically block BCL-2.

What is the tumor microenvironment?

The tumor microenvironment refers to the surrounding cells, tissues, and signaling molecules that support leukemia cell survival. Cells within the bone marrow and lymph nodes provide protective signals that help CLL cells resist treatment, making this environment an important target for newer therapies.

Modern CLL Treatments

How do BTK inhibitors work?

BTK inhibitors block Bruton tyrosine kinase, a key enzyme in the B-cell receptor signaling pathway. By interrupting these survival signals, they reduce the ability of CLL cells to grow and remain protected within lymph nodes and bone marrow.

Why can lymphocyte counts increase after starting a BTK inhibitor?

Many patients experience a temporary increase in lymphocyte counts shortly after beginning BTK inhibitor therapy. This occurs because leukemia cells leave the lymph nodes and enter the bloodstream, a process called redistribution lymphocytosis. Although the blood count rises temporarily, it usually reflects the drug’s expected mechanism of action rather than worsening disease.

How does venetoclax differ from BTK inhibitors?

Venetoclax works by blocking the BCL-2 protein, allowing leukemia cells to undergo their natural process of programmed cell death. Unlike most BTK inhibitors, which are often taken continuously, venetoclax is commonly used in fixed-duration treatment regimens, frequently in combination with other therapies.

Why are PI3K inhibitors used less often today?

Although PI3K inhibitors can be effective in certain patients, their use has declined because they are associated with immune-related side effects such as colitis, pneumonitis, liver inflammation, and severe infections. Newer targeted therapies generally provide similar or better effectiveness with improved safety profiles.

Precision Medicine and Monitoring

Why is genetic testing performed before starting CLL treatment?

Testing for biomarkers such as TP53 mutations, deletion 17p [del(17p)], and IGHV mutation status helps physicians estimate prognosis and choose therapies that are more likely to be effective. These results have become an essential part of personalized treatment planning.

What is measurable residual disease (MRD)?

Measurable residual disease (MRD) refers to the small number of leukemia cells that may remain after treatment but cannot be detected using conventional blood tests or microscopy. Highly sensitive laboratory techniques can identify these cells and provide a more accurate assessment of treatment response.

Does achieving undetectable MRD mean CLL has been cured?

No. Undetectable MRD means that leukemia cells cannot be detected using the sensitivity of current testing methods, but very small numbers of cancer cells may still remain. Although patients with undetectable MRD often experience longer remissions, continued follow-up remains important.

Future Directions

What advances are researchers pursuing to improve CLL treatment?

Researchers are studying new combinations of targeted therapies, next-generation BTK and BCL-2 inhibitors, immune-based treatments such as CAR T-cell therapy and bispecific antibodies, and improved genomic profiling. These efforts aim to overcome drug resistance, personalize treatment, reduce side effects, and achieve longer-lasting remissions for people living with CLL.

Can chronic lymphocytic leukemia be cured?

For most patients, CLL is considered a chronic disease rather than a curable one. Modern targeted therapies can control the disease for many years, often producing deep and durable remissions, but they generally do not eliminate every leukemia cell. Researchers continue to study new treatment combinations and immune-based therapies that may improve long-term outcomes, and some patients can remain in remission for extended periods after completing treatment.

References

Blombery, P., Chatzikonstantinou, T., Gerousi, M., Rosenquist, R., Gaidano, G., Pospisilova, Š., … & European Research Initiative on CLL. (2025). Resistance to targeted therapies in chronic lymphocytic leukemia: Current status and perspectives for clinical and diagnostic practice. Leukemia, 39(9), 2049–2060. https://doi.org/10.1038/s41375-025-02662-y

Hallek, M., Cheson, B. D., Catovsky, D., Caligaris-Cappio, F., Dighiero, G., Döhner, H., Hillmen, P., Keating, M. J., Montserrat, E., Rai, K. R., & Kipps, T. J. (2018). iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. Blood, 131(25), 2745–2760. https://doi.org/10.1182/blood-2017-09-806398

Rios-Olais, F. A., McGary, A. K., Tsang, M., Almader-Douglas, D., Leis, J. F., Buras, M. R., & Hilal, T. (2024). Measurable residual disease and clinical outcomes in chronic lymphocytic leukemia: A systematic review and meta-analysis. JAMA Oncology, 10(9), 1221–1227. https://doi.org/10.1001/jamaoncol.2024.2122

U.S. Food and Drug Administration. (2023, January 19). FDA approves zanubrutinib for chronic lymphocytic leukemia or small lymphocytic lymphoma. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-zanubrutinib-chronic-lymphocytic-leukemia-or-small-lymphocytic-lymphoma

Wierda, W. G., Stephens, D. M., Eichhorst, B., Brown, J. R., Barrientos, J. C., Byrd, J. C., & National Comprehensive Cancer Network. (2024). NCCN Clinical Practice Guidelines in Oncology: Chronic lymphocytic leukemia/small lymphocytic lymphoma (Version 2.2024). Journal of the National Comprehensive Cancer Network, 22(3), 175–204. https://doi.org/10.6004/jnccn.2024.0018

Zhang, S., & Kipps, T. J. (2014). The pathogenesis of chronic lymphocytic leukemia. Annual Review of Pathology: Mechanisms of Disease, 9, 103–118. https://doi.org/10.1146/annurev-pathol-020712-163955